BenevolentAI Investor Presentation Deck
Cashflows focused upon drug and platform development
Normalised¹ operating loss
Depreciation & amortisation
Foreign exchange
Equity share-based payment
Cash flows from changes in working capital
Cash expended from underlying operating activities
Opening cash balance
Closing cash balance
1) Excludes exceptional costs related to the Business Combination
Six months ended 30 June
2022
£'000
(55,280)
1,506
(1,589)
21,913
(12,312)
(45,762)
40,553
165,338
£0.3m lab equipment; £0.1m computer;
£1.1m property-related leases
£3m charge from Euro holdings, £1.8m
gain from operational
Non-Transaction-related equity awards
removed from the P&L (no cash impact)
Largely driven by outstanding R&D tax
credit receivable (£12m) expected in 2H
and other payable decreases
End-June cash position of £165.3m
provides ample liquidity to meet
multiple key value inflection points
Benevolent 29View entire presentation